Federal Register / Vol. 80, No. 77 / Wednesday, April 22, 2015 / Notices 22539 

Countermeasure without geographic 

limitation. 

Liability immunity is afforded to 

manufacturers and distributors without 

regard to whether the countermeasure is 

used by or administered in any 

designated geographic area; liability 

immunity is afforded to program 

planners and qualified persons when 

the countermeasure is used by or 

administered in any designated 

geographic area, or the program planner 

or qualified person reasonably could 

have believed the recipient was in that 

geographic area. 

XII. Effective Time Period 

42 U.S.C. 247d–6d(b)(2)(B) 

Liability immunity for Covered 

Countermeasures begins on the effective 

date and extends for twelve (12) months 

from that date. 

XIII. Additional Time Period of 

Coverage 

42 U.S.C. 247d–6d(b)(3)(B) and (C) 

I have determined that an additional 

twelve (12) months of liability 

protection is reasonable to allow for the 

manufacturer(s) to arrange for 

disposition of the Covered 

Countermeasure, including return of the 

Covered Countermeasures to the 

manufacturer, and for Covered Persons 

to take such other actions as are 

appropriate to limit the administration 

or use of the Covered Countermeasures. 

Covered Countermeasures obtained 

for the Strategic National Stockpile 

(‘‘SNS’’) during the effective period of 

this Declaration are covered through the 

date of administration or use pursuant 

to a distribution or release from the 

SNS. 

XIV. Countermeasures Injury 

Compensation Program 

42 U.S.C 247d–6e 

The PREP Act authorizes a 

Countermeasures Injury Compensation 

Program (‘‘CICP’’) to provide benefits to 

certain individuals or estates of 

individuals who sustain a covered 

serious physical injury as the direct 

result of the administration or use of the 

Covered Countermeasures, and benefits 

to certain survivors of individuals who 

die as a direct result of the 

administration or use of the Covered 

Countermeasures. The causal 

connection between the countermeasure 

and the serious physical injury must be 

supported by compelling, reliable, valid, 

medical and scientific evidence in order 

for the individual to be considered for 

compensation. The CICP is 

administered by the Health Resources 

and Services Administration (‘‘HRSA’’), 

within the Department of Health and 

Human Services. Information about the 

CICP is available at the toll free number 

1–855–266–2427 or http://

www.hrsa.gov/cicp/. 

XV. Amendments 

42 U.S.C. 247d–6d(b)(4) 

Any amendments to this Declaration 

will be published in the Federal 

Register. 

Authority: 42 U.S.C. 247d–6d. 

Dated: April 9, 2015. 

Sylvia M. Burwell, 

Secretary. 

[FR Doc. 2015–09412 Filed 4–21–15; 8:45 am] 

BILLING CODE 4150–03–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Public Availability of the Department of 

Health and Human Services FY 2014 

Service Contract Inventory 

AGENCY: Office of the Assistant 

Secretary for Financial Resources, Office 

of Grants and Acquisition Policy and 

Accountability, Division of Acquisition, 

Department of Health and Human 

Services. 

ACTION: Notice of Public Availability of 

FY 2014 Service Contract Inventories. 

SUMMARY: In accordance with Section 

743 of Division C of the Consolidated 

Appropriations Act of 2010 (Public Law 

111–117), Department of Health and 

Human Services (HHS) is publishing 

this notice to advise the public of the 

availability of its FY 2014 Service 

Contract Inventory. This inventory 

provides information on service contract 

actions over $25,000 that were made in 

FY 2014. The information is organized 

by function to show how contracted 

resources are distributed throughout the 

agency. The inventory has been 

developed in accordance with guidance 

issued on November 5, 2010 and 

December 19, 2011 by the Office of 

Management and Budget’s Office of 

Federal Procurement Policy (OFPP). 

OFPP’s guidance is available at http://

www.whitehouse.gov/sites/default/files/

omb/procurement/memo/servicecontract-inventories-guidance11052010.pdf. HHS has posted its 

inventory and a summary of the 

inventory on the HHS homepage at the 

following link: http://www.hhs.gov/

grants/servicecontracts/. 

FOR FURTHER INFORMATION CONTACT: 

Questions regarding the service contract 

inventory should be directed to Lori 

Sakalos, Director in the HHS/Office of 

the Secretary, Assistant Secretary for 

Financial Resources, Office of Grants 

and Acquisition Policy and 

Accountability, Office of Acquisition 

Policy at 202–690–6361 or 

Lori.Sakalos@hhs.gov. 

Dated: April 16, 2015. 

Angela Billups 

Associate Deputy Assistant Secretary for 

Acquisition, Senior Procurement Executive, 

Assistant Secretary for Financial Resources, 

Office of the Secretary. 

[FR Doc. 2015–09415 Filed 4–21–15; 8:45 am] 

BILLING CODE 4150–28–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 552b(c) 

(4) and 552b(c) (6), Title 5 U.S.C., as 

amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; NCI EDRN 

Review I. 

Date: June 9, 2015. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Delia Tang, MD, Scientific 

Review Officer, Research Programs Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W602, Rockville, MD 

20850, 240–276–6456 tangd@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Initial Review Group; NCI 

Subcommittee F-Institutional Training and 

Education. 

Date: June 9, 2015. 

Time: 11:30 a.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute, Shady 

Grove, 9609 Medical Center Drive, Room 

7W606, Rockville, MD 20850, (Telephone 

Conference Call). 

Contact Person: Timothy C. Meeker, Ph.D., 

MD, Scientific Review Officer, Resource and 

Training Review Branch, Division of 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
22540 Federal Register / Vol. 80, No. 77 / Wednesday, April 22, 2015 / Notices 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W606, Rockville, MD 20850, 240– 

276–6464, meekert@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; 

Exploratory/Development Research Grant 

Program Omnibus SEP–6. 

Date: June 9–10, 2015. 

Time: 4:30 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel Bethesda, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Dona Love, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W236, Rockville, MD 

20850, 240–276–5264, donalove@

mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; NCI EDRN 

Review II. 

Date: June 9–10, 2015. 

Time: 5:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Delia Tang, MD, Scientific 

Review Officer, Research Programs Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W602, Rockville, MD 

20850, 240–276–6456, tangd@mail.nih.gov. 

Name of Committee: National Cancer 

Institute special Emphasis Panel; 

Exploratory/Development Research Grant 

Program Omnibus SEP–3. 

Date: June 29–30, 2015. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Viatcheslav A. 

Soldatenkov, Ph.D., MD, Scientific Review 

Officer, Special Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W254, Rockville, MD 20850, 240– 

276–6378, soldatenkovv@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Omnibus 

SEP–13 Review. 

Date: July 9, 2015. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20852. 

Contact Person: David G. Ransom, Ph.D., 

Scientific Review Officer, Research Programs 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W124, 

Rockville, MD 20850, 240–276–6351, 

david.ransom@nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Omnibus 

SEP–11 Review. 

Date: July 15, 2015. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute, Shady 

Grove, 9609 Medical Center Drive, Room 

7W122, Rockville, MD 20850, (Telephone 

Conference Call). 

Contact Person: Shakeel Ahmad, Ph.D., 

Scientific Review Officer, Research Programs 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W122, 

Rockville, MD 20850, 240–276–6349, 

ahmads@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; NCI 

Omnibus Drug Development SEP–9. 

Date: July 21, 2015. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott, 5151 Pooks Hill 

Road, Bethesda, MD 20814. 

Contact Person: Timothy C. Meeker, MD, 

Ph.D., Scientific Review Officer, Resource 

and Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W624, Rockville, MD 20850, 240– 

276–6464, meekert@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Omnibus 

SEP–17 Review. 

Date: July 21, 2015. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute, Shady 

Grove, 9609 Medical Center Drive, Room 

7W610, Rockville, MD 20850, (Telephone 

Conference Call). 

Contact Person: Caterina Bianco, MD, 

Ph.D., Scientific Review Officer, Research 

Programs Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W610, Rockville, MD 20850, 240– 

276–6459, biancoc@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: April 16, 2015. 

Melanie J. Gray, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–09236 Filed 4–21–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA RM13– 

006: Pioneer Awards. 

Date: May 6–8, 2015. 

Time: 8:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Arnold Revzin, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4146, 

MSC 7806, Bethesda, MD 20892, (301) 435– 

1153, revzina@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Auditory Neuroscience. 

Date: May 7–8, 2015. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20895, 

(Virtual Meeting). 

Contact Person: John Bishop, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5182, 

MSC 7844, Bethesda, MD 20892, (301) 408– 

9664, bishopj@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: April 16, 2015. 

Carolyn Baum, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–09237 Filed 4–21–15; 8:45 am] 

BILLING CODE 4140–01–P 


asabaliauskas on DSK5VPTVN1PROD with NOTICES